These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26715564)

  • 1. Propagation of Aβ, tau and α-synuclein pathology between experimental models and human reality: prions, propagons and propaganda.
    Uchihara T; Giasson BI; Paulus W
    Acta Neuropathol; 2016 Jan; 131(1):1-3. PubMed ID: 26715564
    [No Abstract]   [Full Text] [Related]  

  • 2. The Prion 2018 round tables (II): Aβ, tau, α-synuclein… are they prions, prion-like proteins, or what?
    Eraña H
    Prion; 2019 Jan; 13(1):41-45. PubMed ID: 30646820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
    Eisele YS; Duyckaerts C
    Acta Neuropathol; 2016 Jan; 131(1):5-25. PubMed ID: 26715565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion-like mechanisms in neurodegenerative diseases.
    Frost B; Diamond MI
    Nat Rev Neurosci; 2010 Mar; 11(3):155-9. PubMed ID: 20029438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prions and Non-infectious Amyloids of Mammals - Similarities and Differences.
    Galkin AP; Velizhanina ME; Sopova YV; Shenfeld AA; Zadorsky SP
    Biochemistry (Mosc); 2018 Oct; 83(10):1184-1195. PubMed ID: 30472956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse models for studying the formation and propagation of prions.
    Watts JC; Prusiner SB
    J Biol Chem; 2014 Jul; 289(29):19841-9. PubMed ID: 24860095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins.
    Corbett GT; Wang Z; Hong W; Colom-Cadena M; Rose J; Liao M; Asfaw A; Hall TC; Ding L; DeSousa A; Frosch MP; Collinge J; Harris DA; Perkinton MS; Spires-Jones TL; Young-Pearse TL; Billinton A; Walsh DM
    Acta Neuropathol; 2020 Mar; 139(3):503-526. PubMed ID: 31853635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The red-hot debate about transmissible Alzheimer's.
    Abbott A
    Nature; 2016 Mar; 531(7594):294-7. PubMed ID: 26983522
    [No Abstract]   [Full Text] [Related]  

  • 9. Insights into the thermodynamics of copper association with amyloid-β, α-synuclein and prion proteins.
    Hong L; Simon JD
    Metallomics; 2011 Mar; 3(3):262-6. PubMed ID: 21116546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.
    Colom-Cadena M; Gelpi E; Charif S; Belbin O; Blesa R; Martí MJ; Clarimón J; Lleó A
    J Neuropathol Exp Neurol; 2013 Dec; 72(12):1203-12. PubMed ID: 24226269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau
    Stopschinski BE; Holmes BB; Miller GM; Manon VA; Vaquer-Alicea J; Prueitt WL; Hsieh-Wilson LC; Diamond MI
    J Biol Chem; 2018 Jul; 293(27):10826-10840. PubMed ID: 29752409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prion-like propagation hypothesis in Alzheimer's and Parkinson's disease.
    Duyckaerts C; Clavaguera F; Potier MC
    Curr Opin Neurol; 2019 Apr; 32(2):266-271. PubMed ID: 30724769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding realm of prion phenomena in neurodegenerative disease.
    Frost B; Diamond MI
    Prion; 2009; 3(2):74-7. PubMed ID: 19448400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegeneration. Could they all be prion diseases?
    Miller G
    Science; 2009 Dec; 326(5958):1337-9. PubMed ID: 19965731
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntingtin protein.
    Jerom JP; Madhukumar S; Nair RH; Narayanan SP
    Drug Discov Today; 2023 Dec; 28(12):103802. PubMed ID: 37858630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target.
    Holmes BB; Diamond MI
    J Biol Chem; 2014 Jul; 289(29):19855-61. PubMed ID: 24860099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Tau and α-Synuclein Pathology in the Visual System.
    Rahimi J; Milenkovic I; Kovacs GG
    J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of α-synuclein and tau.
    Sengupta U; Kayed R
    Neuropsychopharmacology; 2019 Jan; 44(1):222-223. PubMed ID: 30206420
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship Between Tau, β Amyloid and α-Synuclein Pathologies.
    Walker L; Attems J
    Adv Exp Med Biol; 2019; 1184():169-176. PubMed ID: 32096037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.